Pacific Biosciences Of California, Inc. (PACB) Stock Price & Analysis
Pacific Biosciences Of California, Inc. (PACB) fell 0.72% to USD 1.37 as of June 10, 2026 at 00:28 UTC, according to Nexqual real-time market data.
PACB last closed at USD 1.38; the session ranged USD 1.31–1.44 on volume of 3,762,996 shares. Market capitalization is $425.52M, with a 52-week range of USD 1.09–2.73 (NMS). Source: Nexqual, June 10, 2026 at 00:28 UTC.
Key Statistics (as of June 10, 2026 at 00:28 UTC)
| Price | USD 1.37 |
|---|---|
| Change | ▼ 0.72% (down) |
| Previous Close | USD 1.38 |
| Open | USD 1.4 |
| Day Range | USD 1.31 – 1.44 |
| 52-Week Range | USD 1.09 – 2.73 |
| Volume | 3,762,996 shares |
| Market Cap | $425.52M |
| Exchange | NMS |
Technical Analysis (PACB)
Nexqual's technical model rates PACB "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 00:28 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 43.94 (neutral) |
| vs SMA50 | Below (USD 1.45) |
| MACD | 0.01 (positive) |
Analyst Ratings (PACB)
Wall Street analysts rate PACB "Buy" based on 6 analysts, with a mean price target of USD 2.46 (range USD 1.5–3), per Nexqual as of June 10, 2026 at 00:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 2.46 |
| High Target | USD 3 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 4 / 2 / 1 |
Earnings (PACB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $40.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-12-31 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.17 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financials & Fundamentals (PACB)
| Total Revenue | $160.03M |
|---|---|
| Revenue Growth (YoY) | +0.10% |
| Gross Margin | +38.33% |
| Operating Margin | -102.89% |
| Profit Margin | -80.34% |
| ROE | -273.55% |
| Debt / Equity | 29,855.79 |
| Current Ratio | 5.65 |
| Total Cash | $275.96M |
| Total Debt | $706.39M |
| Free Cash Flow | $-48.24M |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financial Health Score (PACB)
Nexqual rates Pacific Biosciences Of California, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:28 UTC.
| Growth | Mixed — Revenue +3.9% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $276M cash vs $706M debt |
| Cash Flow | Weak — FCF negative: -$48M, burning cash |
| Efficiency | Critical — ROE -274%, ROA -12.0% |
Ownership (PACB)
| Insider Ownership | +8.77% |
|---|---|
| Institutional Ownership | +54.01% |
| Shares Outstanding | 310.60M |
| Float | 303.44M |
| Short % of Float | +22.18% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Leadership (PACB)
Pacific Biosciences Of California, Inc. is led by Christian O. Henry (age 57), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:28 UTC.
| President, CEO & Director | Christian O. Henry (age 57) |
|---|---|
| CFO & Principal Accounting Officer | James R. Gibson (age 55) |
| Chief Operating Officer | Mark Van Oene (age 52) |
Major Backers & Investors (PACB)
Notable institutional backers of Pacific Biosciences Of California, Inc. include ARK Invest, Softbank Group Corporation, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of June 10, 2026 at 00:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 19.79% |
| Softbank Group Corporation | 6.58% |
| Sumitomo Mitsui Trust Group, Inc. | 2.27% |
| Amova Asset Management Americas Inc | 2.27% |
| Millennium Management | 1.58% |
| Fidelity | 1.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.64% |
| Vanguard Group | 8.1% |
| Geode Capital | 2.25% |
| State Street | 1.97% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
From Pacific Biosciences Of California, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
- The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
- It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
- In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
| EDIT | Editas Medicine, Inc. | USD 2.65 | ▼ 2.21% |
| CRSP | CRISPR Therapeutics AG | USD 51.48 | ▼ 0.69% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:28 UTC. This page is informational and not investment advice.